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s u m m a r y 
Objectives: To characterize the plasmatic proﬁle of cell-derived microvesicles (MVs) at diagnosis and dur- 
ing the treatment of patients with infective endocarditis (IE). 
Methods: Blood samples from 57 patients with IE were obtained on 3 consecutive moments: upon admis- 
sion (T0), at 2 weeks (T1), and at the end of treatment (T2), and were compared with 22 patients with 
other bacterial infections. MPs were measured by ﬂow cytometry and labeled for speciﬁc cell markers 
of CD45 (leukocytes), CD66b (neutrophils), CD14 (monocytes), CD41a (platelets), CD51 (endothelial cells), 
CD3 (T lymphocyte) and CD235a (erythrocytes). 
Results: MVs from platelets (pltMVs), leukocytes (leukMVs), neutrophils (neutMVs), monocytes 
(monoMVs) and lymphocytes (lymphMVs) were signiﬁcantly more elevated in the patients with IE, com- 
pared to the patients with other bacterial infections, despite comparable age, sex, blood counts and C- 
reactive protein levels. MVs values revealed a relatively stable pattern over time in IE, except for a sig- 
niﬁcant increase in leukMVs and neutMVs in T1. LeukMVs ( p = 0.011), neutMVs ( p = 0.010), monoMVs 
( p = 0.016) and lymphMVs ( p = 0.020), measured at admission, were signiﬁcantly higher in IE patients 
that died during hospitalization in comparison with those that survived. In a multivariable analyses, the 
levels of neutMVs remained as an independent factor associated with mortality (odds ratio 2.203; 95% 
conﬁdence interval 1.217 - 3.988; p = 0.009), adjustment for heart failure during the treatment. 
Conclusions: Plasma levels of pltMVs, leukMVs, neutMVs, monoMVs and lymphMVs were signiﬁcantly 
more elevated in patients with IE than in patients with other bacterial infections at hospital admission. 
Furthermore, neutMVs at admission have been identiﬁed as an independent predictor of mortality in 
patients with IE. Thus, cell derived MPs may become an important tool in the differential diagnosis and 
mortality risk assessment early in the course of IE suspected cases. 
© 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved. 
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Infective endocarditis (IE) is the microorganism infection of the
ndocardium known for its high morbidity and mortality in spite
f treatment. 1 The clinical presentation and outcome are largely
etermined by the immune and inﬂammatory response inﬂuenced
y the host-pathogen interaction. The complex pathogenesis of∗ Corresponding author. 
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jinf.2019.06.005 his condition is a challenge, and understanding the immune-
nﬂammatory cell pathways can be a step closer to improve disease
anagement. 
In the last decades, studies have demonstrated a role of cell-
erived microvesicles (MVs) in the immune-inﬂammatory response
n several diseases. MVs are small vesicles, typically around 100–
0 0 0 nm in size, released from the plasma membrane by activated,
njured, or apoptotic cells. 2,3 Although there is no consensual deﬁ-
ition of MVs, 4 MVs are larger than exosomes, their density is un-
nown and they are usually isolated at 10,0 0 0 to 20,0 0 0 x g byeserved. 
. Teixeira-Carvalho et al., Cell-derived microvesicles in infective 
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e  centrifugation. MVs are often called microparticles (MPs), although
the term “microparticles” has also been used for total populations
of vesicles isolated from human plasma at 10 0,0 0 0 x g and such
populations will contain exosomes. 5 
The release of MVs have been demonstrated in physiological 6 
and pathological conditions acting as intercellular messengers. 7 
The number and constitution of the released MVs depends on the
cell type and its state, and on the environmental conditions. 8 MVs
have been studied in sepsis, 9–12 where they were demonstrated to
be associated with microvascular dysfunction, organ damage 9 and
coagulation abnormalities. 13 MVs have also been associated with
thromboembolic events in patients with cancer, 14 and with plaque
instability in coronary artery disease. 15 Some studies demonstrated
that the total number of MVs, including the MVs derived from
platelets, monocytes and endothelium, was signiﬁcantly higher in
patients with type 2 diabetes mellitus than in non-diabetic con-
trols. 16,17 In chronic obstructive lung disease, endothelium derived
MVs have been associated with the grade of lung destruction, air-
ﬂow limitation and disease exacerbation. 18 
Taking all together, it is possible that MVs participate in the
pathophysiology of IE. However, up to this date, there are no stud-
ies evaluating the proﬁle of plasmatic MVs in IE. Therefore, the aim
of our study was to characterize the proﬁle of MVs released by dif-
ferent cells in IE, compare their kinetics during the disease treat-
ment, and evaluate their potential for predicting clinical outcome. 
Methods 
Between August 2011 and January 2017, 65 patients with def-
inite IE, according to the Duke ´s Modiﬁed Criteria, 19 consecutively
admitted to the University Hospital, Federal University of Minas
Gerais, Brazil were evaluated for inclusion in the study. Exclusion
criteria were IE patients who were taking antibiotics for more than
one week prior to the moment of inclusion in the study, and those
who died or underwent cardiac surgery before the collection of the
ﬁrst blood sample for MVs measurement. The Institutional Ethics
Committee approved the study protocol and written informed con-
sent was obtained from all the participants. 
After being included in the study, the patients were followed
during hospitalization, and their clinical, laboratorial and echocar-
diographic data were recorded in the study protocol. Blood sam-
ples for MVs measurement were obtained at 3 consecutive times,
as follows: 
T0 At the diagnosis of infective endocarditis 
T1 At the 15th day of antibiotic treatment 
T2 Before hospital discharge 
Blood sample for MVs quantiﬁcation was collected before the
beginning of the antibiotics or within the ﬁrst week of treatment,
we meant that the T0 sample was collected at the time of diag-
nosis, preferably before the beginning of the antibiotics. Patients
who had already been taking antibiotics at the time of diagnosis
had the T0 sample collected only if they had been taking it for
less than 7 days, otherwise they were excluded from the study. At
the later situation, it was not collected at the same day for every
single patient because the time from antibiotic initiation and the
deﬁnition of the IE diagnosis varied among them. Then, T1 sam-
ples were collected at day 15th of antibiotic treatment for every
single patient, and T2 after completing the treatment, before hos-
pital discharge. 
The endpoint analyzed in this study was overall mortality re-
lated to any complication of IE during hospitalization. 
The data of the patients with IE were compared with those of
a control group, consisting of 22 patients with other bacterial in-
fections that presented with fever and elevated C-reactive protein
(CRP) serum levels. The other infections comprised pyelonephritisPlease cite this article as: M.H. Guimarães Júnior, T.C.A. Ferrari and A
endocarditis: Role in diagnosis and potential for risk stratiﬁcation at 
jinf.2019.06.005 8 cases), pneumonia (7 cases), catheter-related bloodstream infec-
ion (6 cases), and monoarthritis (1 case) without any organ dys-
unction and any other sign of severity. Samples from the control
roup were collected only once, i.e. by the time of their enrollment
n the study. As for the IE group, blood sample for MVs quantiﬁca-
ion was collected before the beginning of the antibiotics or within
he ﬁrst week of the use of these agents. 
ample preparation and MVs measurement 
Citrated peripheral blood samples (3.2 mL) was centrifuged at
0 0 0 × g for 15 min, and then the plasma was cooled at −20 °C be-
ore storage at −80 °C. Immediately before analyses, the samples
ere thawed at 37 °C and were further centrifuged at 13,0 0 0 × g
or 3 min to obtain platelet-free plasma. The latter was diluted 1:3
n citrated phosphate buffered saline (PBS) containing heparin and
entrifuged at 14,0 0 0 × g for 90 min at 15 °C. The resultant MVs
ellet was then resuspended in 1 × annexin V binding buffer (BD
iosciences, CA). 
MVs were measured by ﬂow cytometry. MVs selection was
ased on particle size, presence of a common surface marker
phosphatidylserine) and speciﬁc surface antigens according to the
ell origin as described elsewhere. 20–22 In the ﬁrst step, the MVs
solated from plasma were gated (R1) based on their forward
FSC) and side (SSC) scatter distribution compared to the distri-
ution of synthetic 0.7–0.9 μm SPHERO TM Amino Fluorescent Parti-
les (Spherotech Inc. Libertyville, IL). After that, events present in
1 were accessed for their positive staining for annexin V (BD Bio-
cience, CA), which binds to phosphatidylserine. To properly place
ates, mouse IgG PE conjugated isotype control monoclonal anti-
odies (mAbs) were used. Finally, annexin V + events were gated
ith conjugated mAbs against the cell markers CD45-PE (leuko-
ytes), CD66b-PE (neutrophil), CD14-PercCP (monocytes), CD3-PE
T lymphocyte) CD41a-PercCP (platelets), CD235a-PECy5 (erythro-
ytes) and CD51/61-PE (endothelial cells). 
All reagents and mAbs used in the ﬂow cytometry experiments
ere from BD Biosciences (Becton-Dickinson, CA), unless otherwise
tated. The samples were analysed in a FACScalibur ﬂow cytome-
er (Becton-Dickinson, CA). Over 10 0,0 0 0 events were acquired on
ach sample to reach at least 20 0 0 events within the MVs gate. 
The cytometer was set to operate at a high ﬂow rate setting for
0 s for each sample. The number of MVs/μL of plasma was calcu-
ated as described elsewhere 23 : MVs/μL = ( N ×400)/(60 ×100), in
hich N is the number of events, 400 is the total volume of the
ube before analysis, 60 is the sample volume analyzed, and 100 is
he original volume of MPs suspension used to perform the phe-
otyping protocol. 
ormal reference values 
As normal reference values we used the ones obtained in the
ame research laboratory (Instituto René Rachou, FIOCRUZ Mi-
as), with similar protocol analyses, derived from 30 healthy blood
onors. MVs reference values were: until 75 counts/μL for leuko-
ytes MVs (leukMVs); until 75 counts/μL for neutrophils MVs
neutMVs); until 75 counts/μL for monocytes MVs (monoMVs);
ntil 45 counts/μL for T lymphocytes MVs (lymphMVs); until 90
ounts/μL for platelets MVs (pltMVs); until 45 counts/μL for ery-
hrocytes MVs (eryMVs); and until 54 counts/μL for endothelium
Vs (endoMVs). 
tatistical analysis 
Categorical variables, expressed as numbers and percentages,
ere compared using chi-square testing, whereas continuous data,
xpressed as median and interquartile range (IQR), were compared. Teixeira-Carvalho et al., Cell-derived microvesicles in infective 
hospital admission, Journal of Infection, https://doi.org/10.1016/j. 
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Table 1 
Baseline characteristics of the study population. 
Variable Value 
Age (years) 50 (39–64) 
Male 33 (58.0) 
Diabetes mellitus 9 (15.8) 
Chronic renal disease 13 (22.8) 
Predisposing conditions 
Rheumatic valve disease 17 (29.8) 
Degenerative valve disease 9 (15.7) 
Mitral valve prolapse 11 (19.2) 
Congenital heart disease 5 (8.7) 
Central venous catheter 7 (12.0) 
Previous infective endocarditis 2 (3.4) 
Clinical ﬁndings 
Fever 45 (80.0) 
Weightloss 30 (53.0) 
Anorexia 37 (65.0) 
Musculoskeletal manifestation 12 (21.0) 
Heart murmur 44 (77.0) 
Microbiologic etiology 
Coagulase-negative Staphylococcus 15 (26.3) 
Streptococcusspp 7 (12.3) 
Staphylococcus aureus 6 (10.5) 
Gram negative rods 5 (8.8) 
Enterococcus spp 3 (5.3) 
Fungi 2 (2.5) 
Negative cultureﬁndings 17 (29.8) 
Complications and outcomes 
In-hospital death 17 (30.0) 
Early surgery 25 (44.0) 
Development of heart failure 29 (51.0) 
Fever > 10 days (on treatment) 8 (14.0) 
Neurologic event 11 (19.0) 
Data are expressed as absolute numbers (percentage) and median (in- 
terquartile range). 
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Table 2 
Demographical and laboratorial features of the patients with IE compared with the 
patients with other bacterial infections. 
Variable Cases ( n = 57) Controls ( n = 22) P value 
Age (years) 51.0 (39–64) 56.6 (23–67) 0.411 
Male (n/%) 33 (58) 10 (41) 0.457 
C-reactive protein (mg/L) 76 (37–183) 139 (50–240) 0.610 
Hemoglobin (g/dl, mean) 10 (9–11) 11.5 (9–13) 0.007 
Leukocytosis (x10 ³/μl) 11 (7–14) 10 (5–13) 0.218 
Platelets (x10 ³/μl) 181 (137–251) 186 (115–267) 0.732 
Creatinin (mg/dl) 1.08 (0.8/1.7) 0.97 (0.8/1.2) 1.0 0 0 
Microvesicles (counts/μL) 
Leukocytes 560 (239–832) 313 (200–503) 0.032 
Neutrophils 275 (138–478) 135 (94–265) 0.023 
Monocytes 202 (121–428) 110 (82–210) 0.051 
Lymphocytes 200 (130–303) 119 (58–241) 0.034 
Erythrocytes 166 (85–305) 111 (58–217) 0.110 
Endothelium 428 (244–728) 242 (212–380) 0.054 
Platelets 536 (341–1119) 317 (218–492) 0.020 
Data are expressed as the median (interquartile range). 
Fig. 1. MVs levels from different phenotypes, at T0 (admission), T1 (two weeks of 
treatment) and T2 (end of treatment) in IE patients. Data are expressed as me- 
dian. Leuk = microvesicles from leukocytes; Neut = microvesicles from neutrophils; 
Mono = microvesicles from monocytes; Lymph = microvesicles from T lympho- 
cytes; Ery = microvesicles from erytrocites; Endo = microvesicles from endothelium; 
Plt = microvesicles from platelets. Statistically signiﬁcant differences ( p < 0.05) be- 
tween the times T0 and T1 are indicated by an asterisk above the symbol related 
to each group. 
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i  sing the Mann-Whitney U test, as appropriate. Logistic regres-
ion model was constructed to test the independent association
etween MVs concentrations and death, after adjustment for other
ovariates. The data were analyzed using SPSS 23.0 statistical soft-
are (SPSS, Chicago, IL) and Prism GraphPad software, version 5
San Diego, CA). 
esults 
The baseline characteristics of the 57 patients classiﬁed as hav-
ng deﬁnitive IE are shown in Table 1 . Median age of the IE pa-
ients was 50 years (IQR 39–64 years), and 33 (58%) individu-
ls were male. Native valve IE was observed in 32 (56%) cases,
ollowed by prosthetic valve IE in 15 patients (26%) and device-
elated IE in 10 (17.5%). The most common predisposing condition
as rheumatic valve disease (29.8%) and the most common comor-
idity was chronic renal disease (22.8%). One patient had HIV in-
ection, none was illicit drug user. The most prevalent agent was
oagulase-negative Staphylococcus, which was isolated in 15 (26%)
f the cases, followed by Streptococcus spp (12%) and S. aureus
10%). Culture-negative IE represented 29.8% of the cases. 
Transesophageal echocardiography was performed in 47 (82%)
f the patients and transthoracic echocardiogram in the remaining
0 (17.5%). Vegetations were identiﬁed in 49 patients (86%) and 20
35%) vegetations were described as > 10 mm. 
There was no signiﬁcant difference between the IE group and
he group with other bacterial infections regarding age, CRP lev-
ls, hemoglobin concentrations, white blood cell counts, platelets
ounts and creatinin levels ( Table 2 ). 
A high proportion ( > 84%) of patients in the IE group and in
he control group of the other bacterial infections presented levels
f all MVs phenotypes above the reference values. The comparisonPlease cite this article as: M.H. Guimarães Júnior, T.C.A. Ferrari and A
endocarditis: Role in diagnosis and potential for risk stratiﬁcation at 
jinf.2019.06.005 f the MV counts between the group of other bacterial infections
nd IE patients (at admission) demonstrated signiﬁcantly higher
evels of the leukMVs ( p = 0.032), neutMVs ( p = 0.023), lymphMVs
 p = 0.034) and pltMVs ( p = 0.020) in the IE patients 
icrovesicle counts during treatment 
During hospital stay, 17 patients died with an overall mortality
ate of 30%. Twenty-ﬁve patients (44%) were submitted to cardiac
urgery, chieﬂy due to development of heart failure (51%). The me-
ian time between the diagnosis and the surgery was 9 days (IQR
–17 days). Neurologic events occurred in 11 (19.3%) patients and
he most prevalent was ischemic stroke, which was observed in 9
15.8%) individuals. 
Fig. 1 shows MVs levels during treatment course. LeukMVs,
ltMVs and endoMVs presented the highest levels. There were a
igher count of leukMVs ( p = 0.049) and neutMVs ( p = 0.033) in T0
ompared with T1. 
To analyze the potential value of MVs in predicting early mor-
ality, initially we compared MV levels at admission (T0) and at
1 between the patients who died within the ﬁrst 2 weeks and
hose who survived at least 2 weeks after diagnosis. We found that
he counts of leukMVs ( p = 0.018), neutMVs ( p = 0.009), monoMVs
 p = 0.015) and lymphMVs ( p = 0.019) measured at T0 were signif-
cantly higher in the patients who died compared to those who. Teixeira-Carvalho et al., Cell-derived microvesicles in infective 
hospital admission, Journal of Infection, https://doi.org/10.1016/j. 
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Fig. 2. Comparison between levels of microvesicles (MVs) at T0 (admission), in infective endocarditis patients who survival (white bars) or died (grey bars) during hospi- 
talization. The results are expressed as percentage in box plot format. The box extends from the 25th percentile to 75th percentile, with a horizontal line at the median 
(50th percentile). Whiskers extend from the lowest value to the 25th percentile and from the 75th percentile to the highest value, showing the range of data distribution. 
Statistical signiﬁcance is indicated in each graph. 
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out. survived ( Fig. 2 ). MV levels at different times (T0, T1, T2) are
shown in Fig. 3 (A and B). Although pltMVs levels at T1 were
higher in those who died, this difference was not signiﬁcant, as
there were a wide variation in pltMVs during the disease evolu-
tion. Additionally, mean platelet volume (MPV) values, which were
8.7 ±2.6fL presented no differences between the patients who died
and survived. 
There were no signiﬁcant differences in MV levels at admission
concerning the need of surgery, cerebral event, or development of
heart failure. In the logistic regression analyses, the levels of neut-
MVs at admission remained as an independent predictor of death,
after adjustment for worsening of heart failure during the course
of IE (odds ratio 2.203; 95% CI 1.217–3.988; p = 0.009). 
Discussion 
As far as we know, this is the ﬁrst study describing the plasma
concentrations and kinetics of MVs in patients with IE, and also
comparing IE MV levels with those observed in other bacterial in-
fections. All MVs phenotypes demonstrated elevated plasma lev-
els during infection (IE and the other bacterial infections groups)
when compared with reference values deﬁned in a healthy popu-
lation. Despite comparable age, sex, white blood cell count and CRP
levels, we observed signiﬁcantly higher baseline levels of leukMVs,
neutMVs, lymphMVs and pltMVs in the IE group. This suggests a
greater activation of these cells in IE resulting in higher MVs pro-
duction. MVs levels stratiﬁed by mortality showed higher levels of
leukMVs, neutMVs, monoMVs and lymphMVs at admission in the
patients who died compared with those who survived. After ad-
justment for development of heart failure, which is the main com-
plication of IE, neutMVs at baseline remained predictor of death. 
Extracellular vesicles (EVs) encompass a broad range of vesicles
released from cells. 3 EVs can be classiﬁed into different subsetsPlease cite this article as: M.H. Guimarães Júnior, T.C.A. Ferrari and A
endocarditis: Role in diagnosis and potential for risk stratiﬁcation at 
jinf.2019.06.005 ccording to their size, cellular origin, content or the mechanism
eading to their formation. At present, at least 3 main subgroups of
Vs have been deﬁned. MVs, also referred to as microparticles, are
esicles typically around 100–1000 nm in size. 3,24,25 Exosomes are
maller cell-derived vesicles that are present in all biological ﬂuids.
heir diameter is between 30 and 100 nm, the density ranges be-
ween 1.13 and 1.19 g/ml and the morphology has been described
s cup-shaped. Apoptotic bodies are larger vesicles containing nu-
lear materials. In our study we have analyzed EVs from 500 nm
o 900 nm, thus our population was constituted of MVs, without
verlap with exosomes. 
In the IE patients, the highest levels of MVs were derived
rom leukocytes, followed by those derived from platelets and en-
othelial cells. Studies that evaluated patients with sepsis 26 and
eningococcal disease 27 demonstrated similar ﬁndings. The eleva-
ion of neutMVs levels found in our patients with IE is also similar
o the results of Timár et al. 28 that demonstrated a 6-fold increase
n the release of neutMVs, comparing patients with S. aureus bac-
eremia with healthy individuals. 
In some studies concerning other diseases in which MVs counts
ere performed, the authors observed a predominant increase in
ltMVs differently from what was observed in the present study,
n which leukMV counts were very similar to those of pltMVs in
oth cases and controls with other infections. As those studies
ncluded patients who were critically-ill, including meningococcal
nfection with septic shock, 27 acute Plasmodium vivax malaria, 20 
nd sepsis admitted to an intensive care unit, 26 and probably
resented an acute phase response more exacerbated than that
xhibited by our cases, the intensity of the acute phase re-
ponse and the more acute character of the infection may be
ossible explanations for the observed difference. However, the
ossibility of inﬂuence by pre-analytical factors cannot be ruled. Teixeira-Carvalho et al., Cell-derived microvesicles in infective 
hospital admission, Journal of Infection, https://doi.org/10.1016/j. 
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Fig. 3. A. Radar graphics showing MVs levels according to the cell origin at different times (T0, T1, T2) in survivals and non-survival patients. T0 = admission; T1 = 2 weeks 
of treatment; T3 = end of treatment; Leu = MVs from leukocytes; Neu = MVs from neutrophils; Mon = MVs from monocytes; Lym = MVs from T lymphocytes; Eri = MVs from 
erytrocites; End = MVs from endothelium; Pla = MVs from platelets. 
3B Kinetics of circulating microvesicles (MVs) from endocarditis patients, according to non-fatal and fatal cases at different times (T0, T1, T2). T0 = admission; T1 = 2 weeks of 
treatment; T2 = end of treatment. The results are expressed as percentage in box plot format. The box extends from the 25th percentile to 75th percentile, with a horizontal 
line at the median (50th percentile). Whiskers extend from the lowest value to the 25th percentile and from the 75th percentile to the highest value, showing the range of 
data distribution. Outliers values was plotted as individual points. 
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There are few studies reporting MVs kinetics, determined by
ow cytometry, during treatment of infectious diseases; further-
ore, most of them are cross-sectional and none of them in
E. We observed increase in the leukMVs and neutMVs serumPlease cite this article as: M.H. Guimarães Júnior, T.C.A. Ferrari and A
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as the course of pltMVs in surviving patients. Overtime, the plt-
Vs tended to increase which may represent a protective role of
ltMVs during IE. This in agreement with a study that found a
egative correlation between pltMVs and organ dysfunction in the. Teixeira-Carvalho et al., Cell-derived microvesicles in infective 
hospital admission, Journal of Infection, https://doi.org/10.1016/j. 
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 patients who died due to severe sepsis. 29 However, on T1, nonsur-
viving group had an important increase in pltMVs as well, but the
pltMV levels were lowered again at T2. 
It can be speculated a possible inﬂuence of cardiac surgery
on this ﬁnding as in our cohort, 44% of the patients underwent
surgery, in a median of 9 days after the diagnosis (before ob-
taining data of T1). However, the half-life of MVs seems to be
very short. Rank et al. 30 reported that pltMVs half-life in hu-
mans is 5.8 h. 30 A shorter time (90% clearance after 30 min)
was reported in an animal study of exosomos released by ery-
throcytes. 31 Furthermore, Fu et al. 32 did not ﬁnd any difference
in the total MVs concentrations comparing the MP levels before
surgery with those obtained 12 and 72 h after the procedure. A
possible explanation for this ﬁnding is the above described short
half-life of MVs. Thus, we cannot attribute the enhancement of
leukMV and neutMV levels observed in our study to the surgical
procedure. Nevertheless, it is known that cardiopulmonary bypass
surgery provokes an inﬂammatory state that is able to induce MVs
release. 33 
Value of microparticles in predicting mortality 
The mechanisms that stimulate MVs release are cell activation
and apoptosis, in a process involving cytokine and endotoxin re-
lease, complement lysis, oxidative stress and high shear stress, 34,35 
which may predict disease severity. 
The association between MVs levels and clinical outcomes has
been investigated in other diseases. Zafrani et al. 36 demonstrated
that preventing the release of MVs was associated with a de-
crease in microvasculature dysfunction and higher survival in an-
imal models of sepsis. Delabranche et al. 13 found increased leuk-
MVs levels in patients with sepsis that developed disseminated in-
travascular coagulation. In agreement with our ﬁnding that neut-
MVs were predictors of mortality during hospitalization, a previous
study showed a high mortality rate in septic mice injected with
neutMVs. 37 
Other authors have explored the mechanisms that could ex-
plain the association between leukMVs, neutMVs, monoMVs or
lymphMvs and high mortality. When looking for mechanisms,
is important to take into account that the role of MVs de-
pends on their composition, which is related to the cell of ori-
gin and the target cell. MVs from T lymphocytes are capable
of inducing pro-inﬂammatory peptides, nitric oxide-synthesis and
cyclooxygenase-2 expressions, especially in the middle layer of
the vessels. 38 MonoMVs induce, in a concentration-dependent
manner, reactive oxygen species production, cytokine release and
nuclear factor kappa B (NF-Kb) activation in monocytes and
macrophages. 39 
Illustrating the complexity of MVs effects, neutMVs have been
reported to be pro or antiinﬂamatory, depending on the target
cell. 40 Gasser et al. 41 observed that neutMVs are capable of pro-
voking a dose-dependent release of the anti-inﬂammatory cytokine
transforming growth factor β1 (TGF- β1) on macrophages, as well
as a decrease in the release of interleukin (IL)-6, CXCL-8 and tu-
mor necrosis factor alpha (TNF- α). Johnson et al. 37 demonstrated
in animal model that the administration of neutMVs was associ-
ated with increase in bacterial load and IL-10 levels, and a de-
crease in macrophage activation. Otherwise, it was demonstrated
that neutMVs caused a pro-inﬂammatory response on platelets 42 
and endothelial cells. 43 As an effect of the IE antimicrobial ther-
apy, the ongoing bacteria destruction and clearance cause contin-
uing antigen exposure, increasing the stress and pro-inﬂammatory
factors release, resulting in activation of neutrophils and elevation
of neutMV levels during the course of treatment, especially during
the initial phase when the destruction of bacteria is more intense.
However, further research, comparing the MVs levels with thePlease cite this article as: M.H. Guimarães Júnior, T.C.A. Ferrari and A
endocarditis: Role in diagnosis and potential for risk stratiﬁcation at 
jinf.2019.06.005 elease of cytokines, endotoxins, complement lysis, oxidative stress
nd high shear stress could clarify their effects. Irrespective of their
ole, plasmatic counts of MVs, speciﬁcally neutMVs, may be a use-
ul prognostic tool for risk assessment during the hospitalization of
E patients. The possible mechanisms implicated in this poor out-
ome, as well as the ﬁnal MVs effect (by enhancing a pro or an
ntiinﬂamatory state) deservers more investigation. 
In this context, knowledge about the role of platelets in the
evelopment and severity of various conditions, in addition to
hrombosis, continues to appear, especially in relation to the ar-
as of inﬂammation and immune response. 44 As elevated mean
latelet volume (MPV) indicates increased platelet activation, this
ndex has been studied in several disorders. Some authors ob-
erved that the MPV was higher in patients with IE than in
ealth controls and decreased signiﬁcantly after treatment. 45,46 It
as also been demonstrated that IE patients who present em-
olic events had increased MPV values, compared to those who
o not present this complication. 47,48 Furthermore, previous his-
ory of IE, S. aureus infection , end-stage renal disease, depressed
eft ventricular ejection fraction, early surgical intervention, veg-
tation size ≥10 mm, presence of perivalvular abscess, higher on-
dmission platelet count, CRP and MPV levels emerged as inde-
endent predictors of in-hospital poor outcomes. 48 Thus, high MPV
alues may be a biomarker of unfavorable outcome in IE, especially
egarding the increased risk of thromboembolic events. Addition-
lly, it is possible to speculate that platelets may play a role in the
ortality of these patients. However, it was demonstrated that sev-
ral diseases, including local or systemic infections and many drugs
ay potentially affect MPV levels. 48 Thus, further studies taking
nto account the factors that may affect MPV are necessary to as-
ess the actual associations between MPV and IE. 
The lower limit of detection of the cytometer that was used in
ur investigation (0.7 μm) did not allow the detection of smaller
Vs, which is a limitation of the present study. In addition, our
ample size and number of deaths limited the possibility to adjust
or more variables in the multivariable analyses. 
onclusions 
This study demonstrated that MVs derived from platelets,
eukocytes, neutrophils, monocytes and lymphocytes were signif-
cantly more elevated in patients with IE than in patients with
ther bacterial infections. MVs concentration from leukocytes and
eutrophils were higher at IE diagnosis than at 2 weeks of treat-
ent. Moreover, MVs from neutrophils have been identiﬁed as an
ndependent predictor of mortality in patients with IE. Therefore,
ell derived MVs could become an important tool in the differen-
ial diagnosis and mortality risk assessment of patients with sus-
ected IE at admission. However, studies with larger sample size
re needed before drawing deﬁnitive conclusions. 
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